Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Special Drug Use Surveillance of EFIENT Tablet - Prasugrel For Japanese patients with ischemic heart disease in long-term use clinical practice -

Trial Profile

Special Drug Use Surveillance of EFIENT Tablet - Prasugrel For Japanese patients with ischemic heart disease in long-term use clinical practice -

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Prasugrel (Primary) ; Aspirin
  • Indications Acute coronary syndromes; Angina pectoris; Ischaemia; Ischaemic heart disorders; Myocardial infarction; Stroke; Thrombosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PRASFIT-Practice II
  • Sponsors Daiichi Sankyo Company

Most Recent Events

  • 02 Oct 2020 Final two-year follow-up results published in the Circulation Journal.
  • 12 Nov 2019 Results of one year follow up study assessing effectiveness and safety of prasugrel were published in the Circulation Journal
  • 24 Jan 2019 Results of interim analysis of data from case report forms (CRFs) after 3 months published in the Circulation Journal

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top